Arrêt de service lundi 11 juillet de 12h30 à 13h : tous les sites du CCSD (HAL, EpiSciences, SciencesConf, AureHAL) seront inaccessibles (branchement réseau à modifier)
Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalized for COVID-19

Abstract : Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the impact of prior metformin use on the prognosis of patients with type 2 diabetes hospitalised for COVID-19. We used data from the nationwide observational CORONADO cohort that included patients with diabetes hospitalised for COVID-19 between March 10 and April 10, 2020 in 68 French centres. The primary outcome was combined tracheal intubation and/or death within 7 days of admission. A Kaplan\textendash Meier survival curve was reported for death up to day 28. The association between metformin use and outcomes was then estimated in a logistic regression analysis after applying propensity score weighting approach to account for treatment allocation. Among the 2449 patients included, 1496 were metformin users and 953 were not. Compared with non-users, metformin users were younger with a lower prevalence of diabetic complications, but had more severe features of COVID-19 at admission. The most striking feature was a lower mortality rate in metformin users vs. non-users on day 7 (8.2 % vs. 16.1 %, respectively; P \textexclamdown 0.0001) and on day 28 (16.0 % vs. 28.6 %, respectively: P \textexclamdown 0.0001), even after propensity score weighting was applied. Randomised, controlled studies are now needed in order to confirm the benefits associated with metformin and to establish to what extent these protective effects, if any, can be generalised to non-diabetic patients with COVID-19. \textcopyright 2021 Elsevier Masson SAS
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : samedi 4 juin 2022 - 14:51:43
Dernière modification le : lundi 4 juillet 2022 - 10:17:24

Lien texte intégral



Jean-Daniel Lalau, Abdallah Al-Salameh, N. Wiernsperger, T. Goronflot, M. Pichelin, et al.. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalized for COVID-19. Médecine des Maladies Métaboliques, Elsevier, 2021, 15 (3), pp.278--287. ⟨10.1016/j.mmm.2021.02.013⟩. ⟨hal-03688467⟩



Consultations de la notice